

Santen Included in All Four ESG Investment Indices Selected by GPIF

July 3, 2019, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) announced today that the company has been selected as a constituent of all four of the indices selected by Japan's Government Pension Investment Fund (GPIF), one of the world's largest pension funds, as reference for making ESG (environmental, social, and governance) investments into Japan's corporate sector.

The four ESG indices selected by GPIF are: 1) FTSE Blossom Japan Index, a broad index incorporating overall ESG considerations based on FTSE Russell, an investment index calculator wholly owned by the London Stock Exchange; 2) MSCI Japan ESG Select Leaders Index, a similar broad index based on MSCI, a U.S. provider of investment indices; 3) MSCI Japan Empowering Women Index (WIN), an MSCI index monitoring companies' gender diversity performance; and 4) S&P/JPX Carbon Efficient Index, used to evaluate corporate performance in terms of carbon efficiency, according to S&P Dow Jones Indices. The third and fourth indices respectively focus on ESG's social (gender diversity) and environmental (carbon efficiency, etc.) aspects.

With the aim of achieving sustainable development of society, Santen has been actively involved in a variety of environmental, social and governance initiatives. These include addressing environmental issues, promoting diversity, contributing to society, and strengthening corporate governance and information disclosure. Santen was initially selected as 3) WIN in 2017; and 4) S&P/JPX Carbon Efficient Index in 2018. In 2019, Santen was newly included in 1) FTSE Blossom Japan Index and 2) MSCI Japan ESG Select Leaders Index as well, making the company a constituent of all four GPIF ESG indices.

Also, Santen has been selected as a member of the "SNAM Sustainability Index" established by Sompo Japan Nipponkoa Asset Management Co., Ltd. 4 consecutive years since 2016.

Santen will continue to address various social issues related to ESG, contribute to the creation of a sustainable society, and strive to increase corporate value.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

Contact

Christopher Hohman
General Manager, Corporate Communications Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.com Tel. : +81-6-4802-9360